Amie Hayley

NHMRC Peter Doherty Biomedical Early Career Research Fellow and Senior Research Fellow
Swinburne University of Technology

Melbourne, VIC

Contact me for

  • Mentoring
  • Sitting on boards or committees
  • Providing an expert opinion
  • Outreach activities
  • Conference presenting
  • Opportunities to collaborate


Dr Amie Hayley is an NHMRC Peter Doherty Biomedical Early Career Research Fellow (GNT1119960: 2017-2020) and Senior Research Fellow at the Centre for Human Psychopharmacology at Swinburne University. Her research focuses on delineating a novel biochemical-physiological-behavioural pathways relevant to oculomotor function, visual-attentional performance and information processing capabilities under drug conditions in order to quantify the effect on neurobehaviour. She aims to identify mechanisms by which these changes translate to dangerous human behaviour, and is particularly interested in impaired driving. Importantly, her program of research is seeking to develop new technologies to detect and monitor driver state to reduce the impact of drug-affected driving. Dr Hayley is currently examining the appropriateness of objective eye-tracking technology to monitor and detect impairment and accident risk in stimulant drug-affected drivers. 


Dr Hayley also leads an ongoing multidisciplinary collaborative network between Swinburne University and the Department of Critical Care at Monash Health, Casey Hospital, and Forensic Science South Australia at the Attorney General's Department. As part of this collaboration, she has overseen the completion of two substantive Phase 1 investigator-lead clinical trials assessing; 1) the effects of therapeutic (analgesic) doses of intravenous ketamine on behaviour, cognition and driving performance (ACTRN12616001485426) and 2) the neurocognitive, behavioural and sedating effects of doses of intravenous ketamine alone and in combination with either Fentanyl or Dexmedetomidine in healthy adults (DeKaF trial) (ACTRN12617000787381) and the clinical/neurocognitve effects of an intranasal ketamine/dexmedetomidine solution.